HDAC抑制剂帕比司他(LBH589)在体内对MLL重排急性淋巴细胞白血病发挥抗白血病活性并涉及RNF20/RNF40/WAC-H2B泛素化轴
MLL重排急性淋巴细胞白血病(ALL)在婴儿中预后差且需新策略。研究利用MLL重排ALL异种移植小鼠模型,证明组蛋白去乙酰化酶抑制剂帕比司他(LBH589)单药在体内有强抗白血病效应,延长生存并降低总体疾病负荷;体外分子分析显示其活性涉及抑制RNF20/RNF40/WAC E3连接酶复合物导致H2B泛素化耗竭,敲低WAC可模拟该效应并诱导细胞死亡。
要点
- 帕比司他单药在MLL重排ALL异种移植小鼠中延长生存并降低总体疾病负荷。
- 体外分析显示帕比司他经抑制RNF20/RNF40/WAC复合物耗竭H2B泛素化。
- 敲低WAC可模拟H2B泛素化丢失并伴随细胞死亡诱导。
核心结论
- 帕比司他交叉抑制多条表观遗传通路,从而高效靶向MLL重排ALL。
研究设计与样本
- 研究使用MLL重排ALL异种移植小鼠模型评估帕比司他(LBH589)的体内疗效,并进行体外分子分析。
主要发现
- 帕比司他单药在MLL重排ALL异种移植小鼠中显示强抗白血病效应,延长生存并降低总体疾病负荷。
- 体外分析显示帕比司他的抗白血病活性涉及通过抑制RNF20/RNF40/WAC E3连接酶复合物耗竭H2B泛素化。
- 敲低WAC可模拟H2B泛素化丢失并伴随细胞死亡诱导。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
MLL-rearranged acute lymphoblastic leukaemia (ALL) represents an aggressive malignancy in infants (<1 year of age), associated with poor outcome. Current treatment intensification is not further possible, and novel therapy strategies are needed. Notably, MLL-rearranged ALL is characterised by a strongly deregulated epigenome and shows sensitivity to epigenetic perturbators. Here we demonstrate the in vivo efficacy of the histone deacetylase inhibitor panobinostat (LBH589) using xenograft mouse models of MLL-rearranged ALL. Panobinostat monotherapy showed strong anti-leukaemic effects, extending survival and reducing overall disease burden. Comprehensive molecular analyses in vitro showed that this anti-leukaemic activity involves depletion of H2B ubiquitination via suppression of the RNF20/RNF40/WAC E3 ligase complex; a pivotal pathway for MLL-rearranged leukaemic maintenance. Knockdown of WAC phenocopied loss of H2B ubiquitination and concomitant cell death induction. These combined data demonstrate that panobinostat cross-inhibits multiple epigenetic pathways, ultimately contributing to its highly efficacious targeting of MLL-rearranged ALL.
引用
- Garrido Castro P, van Roon EHJ, Pinhanços SS, et al. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis. Leukemia. 2017. PMID: 28690313. doi:10.1038/leu.2017.216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。